Home › Myelodysplastic Syndromes › North Carolina
Myelodysplastic Syndromes clinical trials in North Carolina
19 studies for Myelodysplastic Syndromes are looking for participants at sites in North Carolina.
Cities in North Carolina
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Atrium Health Wake Forest Baptist, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT05320198Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Duke University Medical Center, Durham
- East Carolina University, Greenville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06577441A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Novant Health Care Institute, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07422480Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06846606Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Unc Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- and 4 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Novant Health-Cancer Institute, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06499285ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- University of North Carolina at Chapel Hill, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06656494Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Duke Cancer Institute, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT05308264Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Chapel Hill
- Research Site, Durham
RecruitingPhase 1/2
Ages 16 and older · All sexes · Updated Jul 20, 2026 · NCT07155226Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- and 4 more
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Duke University, Durham
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Wake Forest Baptist Health, Winston-Salem
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Apr 13, 2026 · NCT01890486A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- UNC Hospital, Chapel Hill
- Duke University, Durham
- Atrium Wake Forest Baptist Medical Center, Winston-Salem
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Duke Cancer Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jan 16, 2026 · NCT05143996SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 27, 2025 · NCT01137643From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.